Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia

Life-threatening COVID-19 pneumonia follows an exaggerated immune response to SARS-CoV-2. pGSN levels fall after SARS-CoV-2 infection. Rhu-pGSN improves outcomes in models of inflammation. In an intubated patient with critical COVID-19 pneumonia and progressive hypoxemia despite standard care, impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Catteeuw, Julie V., DiNubile, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of British Infection Association. 2021
Materias:
Case Reports and Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353968/
https://www.ncbi.nlm.nih.gov/pubmed/34396087
http://dx.doi.org/10.1016/j.clinpr.2021.100088
Descripción
Sumario:Life-threatening COVID-19 pneumonia follows an exaggerated immune response to SARS-CoV-2. pGSN levels fall after SARS-CoV-2 infection. Rhu-pGSN improves outcomes in models of inflammation. In an intubated patient with critical COVID-19 pneumonia and progressive hypoxemia despite standard care, improvement became evident during rhu-pGSN infusions with full recovery within a few weeks.

Ejemplares similares